Skip to main content
Clinical Trials/NCT03803449
NCT03803449
Unknown
Phase 4

Patient Satisfaction and Safety With Propofol Based Sedation With or Without Fentanyl for Gastrointestinal Endoscopy :a Prospective ,Randomized ,and Cohort Study

Shandong University0 sites500 target enrollmentJanuary 1, 2019

Overview

Phase
Phase 4
Intervention
50-200mg propofol
Conditions
Patient Satisfaction
Sponsor
Shandong University
Enrollment
500
Primary Endpoint
Satisfaction assessed by the rate of vomit and diazzy after the procedure
Last Updated
7 years ago

Overview

Brief Summary

Patient satisfaction and safety with propofol based sedation with or without fentanyl for gastrointestinal endoscopy

Detailed Description

This study divide patients into two groups, one will be given propofol midazolam and fentanyl; another group was given propofol with midazolam without fentanyl; to observe two groups of patients blood pressure, body movement, and propofol dosage , and the difference in operator satisfaction, and how many people need to give fentanyl again; and two groups of patients after the operation of the reaction, if there are dizziness, nausea, and other adverse reactions; finally, the differences of these two schemes in different populations were analyzed, and the rationalization and individualized medication will be put forward.

Registry
clinicaltrials.gov
Start Date
January 1, 2019
End Date
October 30, 2019
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Shandong University
Responsible Party
Principal Investigator
Principal Investigator

Yanqing Li

Principal Investigator

Shandong University

Eligibility Criteria

Inclusion Criteria

  • Patients aged 18 or older
  • Patients scheduled for an outpatient gastrointestinal endoscopy by the principal investigator.

Exclusion Criteria

  • Patients with a history of colorectal surgery
  • Patients with ASA class 4 or 5,
  • Patients with pre-existing hypoxaemia (SpO2\<90%),
  • Patients with hypotension (SBP\<90mmHg)
  • Patients with bradycardia (HR\<50 bpm)
  • patients with severe chronic renal failure (creatinine clearance\<30 ml/min)
  • patients with uncontrolled hypertension (systolic blood pressure\>170 mm Hg, diastolic blood pressure\>100 mm Hg)
  • patients with pregnancy or lactation
  • Patients hemodynamically unstable
  • Patients unable to give informed consent

Arms & Interventions

Control group

Participants are given standard regimen: 50-200mg propofol and 1 mg midazolam

Intervention: 50-200mg propofol

Control group

Participants are given standard regimen: 50-200mg propofol and 1 mg midazolam

Intervention: 1 mg midazolam

Fentanyl group

Participants are given intervention regimen: 50ug fentanyl, plus 50-200mg propofol and 1 mg midazolam.

Intervention: 50-200mg propofol

Fentanyl group

Participants are given intervention regimen: 50ug fentanyl, plus 50-200mg propofol and 1 mg midazolam.

Intervention: 50ug fentanyl

Fentanyl group

Participants are given intervention regimen: 50ug fentanyl, plus 50-200mg propofol and 1 mg midazolam.

Intervention: 1 mg midazolam

Outcomes

Primary Outcomes

Satisfaction assessed by the rate of vomit and diazzy after the procedure

Time Frame: half a year

Rates of vomit and diazzy of patients after the procedure between the two groups

Secondary Outcomes

  • Safety assessed by the rate of hypoxia during the procedure(half a year)
  • Safety assessed by the rate of hypotention during the procedure(half a year)
  • Safety assessed by the rate of hyoxemia during the procedure(half a year)
  • Safety assessed by the rate of breadycardia during the procedure(half a year)
  • Safety assessed by the rate of required airway management during the procedure(half a year)
  • Safety assessed by the rate of involuntary movement during the procedure(half a year)

Similar Trials